A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: Findings from a multi cohort validity analysis
Open Access Publication
Rights and Permissions
West, T., Kirmess, K.M., Meyer, M.R. et al. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. Mol Neurodegeneration 16, 30 (2021). https://doi.org/10.1186/s13024-021-00451-6 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
West, Tim; Kirmess, Kristopher M; Meyer, Matthew R; Holubasch, Mary S; Knapik, Stephanie S; Hu, Yan; Contois, John H; Jackson, Erin N; Harpstrite, Scott E; Bateman, Randall J; Holtzman, David M; Verghese, Philip B; Fogelman, Ilana; Braunstein, Joel B; and Yarasheski, Kevin E, "A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: Findings from a multi cohort validity analysis." Molecular Neurodegeneration. 16, 1. 30 (2021).
Table S1. Acceptance criteria of Aβ 40 and Aβ 42 assays. Table S2. ApoE proteotype determination based on present/absent of call of isoform-specific peptides. Table S3. Participant characteristics separated by brain amyloid status, for each cohort.